Using audience segmentation to identify implementation strategies to improve PrEP uptake among at-risk cisgender women: a mixed-methods study protocol.
Audience segmentation
Cis women
Implementation strategies
PrEP
Journal
Implementation science communications
ISSN: 2662-2211
Titre abrégé: Implement Sci Commun
Pays: England
ID NLM: 101764360
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
22
08
2023
accepted:
28
10
2023
medline:
18
11
2023
pubmed:
18
11
2023
entrez:
18
11
2023
Statut:
epublish
Résumé
In the USA, 19% of new HIV infections occur among cisgender women (cis women); however, only 10% of eligible cis women have been prescribed pre-exposure prophylaxis (PrEP) for the prevention of HIV infection (an evidence-based intervention). A fundamental challenge for expanding HIV prevention to cis women is ensuring implementation strategies are tailored to the various healthcare settings in which cis women seek care and the heterogeneous providers nested within these settings. This project's specific aims are to (1) explore clinician-level characteristics and organizational climate factors that are related to variability in adoption of PrEP service delivery as an evidence-based intervention for cis women; (2) identify latent audience segments of women's health providers as the related to PrEP acceptability, adoption, and maintenance and analyze demographic correlates of these segments; and (3) identify audience segment-specific implementation strategies to facilitate the adoption of PrEP as an evidence-based intervention among at-risk cis women. Using the i-PARIHS framework, this mixed-methods study examines three domains for guiding audience segmentation to facilitate PrEP implementation for cis women: innovation (degree of fit with existing practices, usability), recipient beliefs and knowledge and context factors (organizational culture, readiness for change), needs to determine appropriate facilitation methods. To achieve aim 1, qualitative interviews will be conducted with PrEP-eligible cis women, women's health providers, and other key stakeholders. Aim 2 will consist of a quantitative survey among 340 women's health providers. Latent class analysis will be used to facilitate audience segmentation. To achieve aim 3, a panel of 5-8 providers for each audience segment will meet and engage in iterative discussions guided by Fernandez's implementation mapping to identify (1) implementation outcomes and performance objectives, determinants, and change objectives and (2) determine and refine of implementation strategies for each audience segment. This exploratory mixed methods study will provide an empirical foundation to inform the development implementations strategies aimed at increasing PrEP delivery to cis women among heterogenous groups of providers.
Sections du résumé
BACKGROUND
BACKGROUND
In the USA, 19% of new HIV infections occur among cisgender women (cis women); however, only 10% of eligible cis women have been prescribed pre-exposure prophylaxis (PrEP) for the prevention of HIV infection (an evidence-based intervention). A fundamental challenge for expanding HIV prevention to cis women is ensuring implementation strategies are tailored to the various healthcare settings in which cis women seek care and the heterogeneous providers nested within these settings. This project's specific aims are to (1) explore clinician-level characteristics and organizational climate factors that are related to variability in adoption of PrEP service delivery as an evidence-based intervention for cis women; (2) identify latent audience segments of women's health providers as the related to PrEP acceptability, adoption, and maintenance and analyze demographic correlates of these segments; and (3) identify audience segment-specific implementation strategies to facilitate the adoption of PrEP as an evidence-based intervention among at-risk cis women.
METHODS
METHODS
Using the i-PARIHS framework, this mixed-methods study examines three domains for guiding audience segmentation to facilitate PrEP implementation for cis women: innovation (degree of fit with existing practices, usability), recipient beliefs and knowledge and context factors (organizational culture, readiness for change), needs to determine appropriate facilitation methods. To achieve aim 1, qualitative interviews will be conducted with PrEP-eligible cis women, women's health providers, and other key stakeholders. Aim 2 will consist of a quantitative survey among 340 women's health providers. Latent class analysis will be used to facilitate audience segmentation. To achieve aim 3, a panel of 5-8 providers for each audience segment will meet and engage in iterative discussions guided by Fernandez's implementation mapping to identify (1) implementation outcomes and performance objectives, determinants, and change objectives and (2) determine and refine of implementation strategies for each audience segment.
DISCUSSION
CONCLUSIONS
This exploratory mixed methods study will provide an empirical foundation to inform the development implementations strategies aimed at increasing PrEP delivery to cis women among heterogenous groups of providers.
Identifiants
pubmed: 37978402
doi: 10.1186/s43058-023-00518-z
pii: 10.1186/s43058-023-00518-z
pmc: PMC10656952
doi:
Types de publication
Journal Article
Langues
eng
Pagination
140Subventions
Organisme : NIMH NIH HHS
ID : R21 MH126789
Pays : United States
Organisme : NIMH NIH HHS
ID : R21MH126789
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Am Psychol. 2020 Nov;75(8):1052-1066
pubmed: 33252944
AIDS Patient Care STDS. 2012 Jul;26(7):395-405
pubmed: 22694239
J Racial Ethn Health Disparities. 2023 Dec;10(6):2744-2761
pubmed: 36396922
Health Educ Behav. 2020 Oct;47(5):765-781
pubmed: 32639167
Curr HIV/AIDS Rep. 2010 Nov;7(4):210-9
pubmed: 20820971
BMJ Sex Reprod Health. 2021 Jul;47(3):e6
pubmed: 33122259
Implement Sci Commun. 2023 Jun 9;4(1):64
pubmed: 37296455
J Health Commun. 2016 May;21(5):564-74
pubmed: 27115046
Womens Health Issues. 2021 May-Jun;31(3):294-300
pubmed: 33839000
PLoS One. 2021 Oct 14;16(10):e0258542
pubmed: 34648589
Front Reprod Health. 2023 Jun 08;5:1196392
pubmed: 37361343
Psychiatr Serv. 2020 Nov 1;71(11):1170-1178
pubmed: 32517640
Front Public Health. 2019 Aug 14;7:209
pubmed: 31475126
Implement Sci Commun. 2023 Feb 16;4(1):16
pubmed: 36797794
Implement Sci. 2011 Aug 30;6:99
pubmed: 21878092
J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):520-8
pubmed: 26247895
J Health Commun. 2009 Jan-Feb;14(1):15-42
pubmed: 19180369
Front Public Health. 2019 Jun 18;7:158
pubmed: 31275915
Int J Environ Res Public Health. 2022 Jul 10;19(14):
pubmed: 35886282
PLoS One. 2021 Mar 18;16(3):e0248626
pubmed: 33735209
Implement Sci. 2017 Nov 3;12(1):125
pubmed: 29100551
J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):20222
pubmed: 26198349
Sex Transm Dis. 2021 Jan;48(1):32-36
pubmed: 33315784
Sex Transm Infect. 2023 Jun;99(4):276-278
pubmed: 36759178
Res Nurs Health. 2000 Jun;23(3):246-55
pubmed: 10871540
Sex Transm Dis. 2023 Nov 1;50(11):726-730
pubmed: 36943788
Soc Mar Q. 2014 Sep 1;20(3):148-164
pubmed: 30057489
Implement Res Pract. 2023 Jul 7;4:26334895231185376
pubmed: 37790187
AIDS Behav. 2021 Oct;25(10):3425-3436
pubmed: 33974167
Ann Epidemiol. 2018 Dec;28(12):841-849
pubmed: 29983236
Glob Adv Health Med. 2021 May 24;10:2164956120980694
pubmed: 34104573
Health Commun. 2013;28(7):709-17
pubmed: 23356504
AIDS Patient Care STDS. 2013 Apr;27(4):248-54
pubmed: 23565928
Curr Opin HIV AIDS. 2022 Mar 1;17(2):72-88
pubmed: 35225248
Health Mark Q. 2022 Apr-Jun;39(2):159-172
pubmed: 34895110
Curr Opin HIV AIDS. 2020 Jan;15(1):19-26
pubmed: 31644481
Struct Equ Modeling. 2014 Jan 1;21(4):534-552
pubmed: 25328371
Curr HIV/AIDS Rep. 2019 Aug;16(4):259-269
pubmed: 31177363
Eval Program Plann. 2022 Feb;90:101982
pubmed: 34391579
AIDS Behav. 2016 Jan;20(1):115-25
pubmed: 26650383
AIDS Patient Care STDS. 2019 Jun;33(6):253-261
pubmed: 31094576
Implement Sci. 2018 Sep 19;13(1):121
pubmed: 30231934
J Health Commun. 1996 Jul-Sep;1(3):267-83
pubmed: 10947364
AIDS Patient Care STDS. 2018 Jan;32(1):16-23
pubmed: 29323558
J HIV AIDS Soc Serv. 2021;19(4):299-319
pubmed: 34456637
Psychol Bull. 2007 Jul;133(4):673-93
pubmed: 17592961
J Behav Health Serv Res. 2017 Apr;44(2):177-194
pubmed: 26289563
Implement Sci. 2016 Mar 10;11:33
pubmed: 27013464
Implement Sci Commun. 2022 Mar 4;3(1):24
pubmed: 35246274
Lancet HIV. 2020 Aug;7(8):e582-e592
pubmed: 32763221